HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
about
Emerging preclinical pharmacological targets for Parkinson's diseaseTargeting New Candidate Genes by Small Molecules Approaching Neurodegenerative DiseasesConformational analysis of misfolded protein aggregation by FRET and live-cell imaging techniquesHDAC6 Inhibitors Rescued the Defective Axonal Mitochondrial Movement in Motor Neurons Derived from the Induced Pluripotent Stem Cells of Peripheral Neuropathy Patients with HSPB1 MutationDifferential effects of binge methamphetamine injections on the mRNA expression of histone deacetylases (HDACs) in the rat striatumHDAC6 inhibition results in tau acetylation and modulates tau phosphorylation and degradation in oligodendrocytesA Rational Approach for the Identification of Non-Hydroxamate HDAC6-Selective InhibitorsGenetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition.Increasing microtubule acetylation rescues axonal transport and locomotor deficits caused by LRRK2 Roc-COR domain mutations.Aggresome formation is regulated by RanBPM through an interaction with HDAC6Microtubule stabilization by Mdp3 is partially attributed to its modulation of HDAC6 in addition to its association with tubulin and microtubules.Quantification of histone deacetylase isoforms in human frontal cortex, human retina, and mouse brainTherapeutic perspectives of epigenetically active nutrients.An in vivo screen to identify candidate neurogenic genes in the developing Xenopus visual system.KLF4 regulates adult lung tumor-initiating cells and represses K-Ras-mediated lung cancer.Histone Deacetylase 6 Regulates Bladder Architecture and Host Susceptibility to Uropathogenic Escherichia coli.Effects of prenatal Poly I:C exposure on global histone deacetylase (HDAC) and DNA methyltransferase (DNMT) activity in the mouse brainAmyloid β oligomers elicit mitochondrial transport defects and fragmentation in a time-dependent and pathway-specific mannerRelationships between Stress Granules, Oxidative Stress, and Neurodegenerative Diseases.Epigenetic alterations in hippocampus of SAMP8 senescent mice and modulation by voluntary physical exercise.HDAC6 regulates IL-17 expression in T lymphocytes: implications for HDAC6-targeted therapies.Inclusion body formation, macroautophagy, and the role of HDAC6 in neurodegeneration.Molecular biomarkers of neurodegeneration.Towards selective inhibition of histone deacetylase isoforms: what has been achieved, where we are and what will be next.Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors.Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders.The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.Histone deacetylase 6 in health and disease.Histone deacetylases function as a novel potential therapeutic target for cancer.Histone deacetylase 6 inhibits influenza A virus release by downregulating the trafficking of viral components to the plasma membrane via its substrate, acetylated microtubules.Microtubule Destabilization Paves the Way to Parkinson's Disease.Characterizing the "POAGome": A bioinformatics-driven approach to primary open-angle glaucoma.Accurate splicing of HDAC6 pre-mRNA requires SONMolecular dynamics of zinc-finger ubiquitin binding domains: a comparative study of histone deacetylase 6 and ubiquitin-specific protease 5.Light-Controlled Histone Deacetylase (HDAC) Inhibitors: Towards Photopharmacological Chemotherapy.Human histone deacetylase 6 shows strong preference for tubulin dimers over assembled microtubules.Histone deacetylase 6 delays motor neuron degeneration by ameliorating the autophagic flux defect in a transgenic mouse model of amyotrophic lateral sclerosis.HDAC6 mediates HIV-1 tat-induced proinflammatory responses by regulating MAPK-NF-kappaB/AP-1 pathways in astrocytes.Inhibiting histone deacetylase 6 partly protects cultured rat cortical neurons from oxygen‑glucose deprivation‑induced necroptosis.
P2860
Q26764724-1C3E30D9-2DA3-4D7C-9FBF-E4E35AFFBB10Q26771812-89E23B07-12CD-42A8-A315-60CBCF8742E9Q28083085-DB433FC0-AAD3-42AB-AB2A-7B8F04F5D7C0Q28468383-38E25BF3-F3AF-4D62-AFAB-4ED05F9945C5Q28571349-2EA208EF-D30E-4C2C-A485-8CE37FB8ADABQ28575023-AE4E32C2-812B-4137-AAC9-39413570BF00Q28830529-EAD61514-6277-4D1A-B7FF-C326623A9E00Q30401432-64A3D474-05AA-411B-9082-4F6D3FABBAD5Q30440318-C3546FC3-D9E9-479A-BBF6-FA7B82F1D039Q30596172-2700955E-0FDF-4629-A0A3-19B39CE5E809Q33757230-7DFC3DF6-4E98-4B0C-B065-A2928A55A55FQ35116461-99A99A23-16D2-499F-BBF6-1FB11E2DCF02Q35593214-3B20A0BE-4ED2-4AB2-AFD7-7AF258BFFCD1Q35631468-EEAC0AFB-800F-4B35-A225-F3BA3473238BQ36096105-5933E152-1558-429B-88C8-3BC707875E1EQ36472473-3794E6CD-E443-49B6-B728-F4F3BDF1C611Q36735425-606B5217-9FB7-4301-ADB2-D54B6D21AAF5Q36999907-63EE67B1-655A-403B-A422-7E659A098565Q37185261-A6C0EB06-F396-4B31-9858-B565684D7367Q37618198-852D93FF-9D7C-40DE-AFD5-2073E09AC4E1Q37650337-58612837-FE9C-48B9-8271-D17239688C19Q37738242-BFF35BBF-D68A-4EAF-985E-1D1D31E66390Q38126332-BF20F9B3-9165-41CA-B367-E71AEF2589F4Q38154930-B7A984B5-849D-4FF9-A2FB-7207A176AAF1Q38204386-E89E25BA-322C-4868-A3AC-1BD45397885BQ38215303-8CB24159-9A1E-4941-BBB8-234562E25708Q38240733-70782C40-58B9-4BFF-8C06-654A62DC7AEBQ38260795-3A6BBC28-F97D-42FB-80FA-7F805D853FACQ38357741-F4CA445D-0CF7-4615-8A2E-D0F518135CC1Q38908331-937F1A7C-4405-4FC2-BE0D-EF864E1184F0Q38974742-2B6523BC-8F0F-4F94-B14E-480E2799171AQ38984991-F5A59F1A-F00C-4334-B0C9-AE74B2468D25Q39145730-72B7C532-D50F-4752-9D31-8F05103F286AQ39555816-3B7FEADA-C4B2-42FF-A99F-55BDB0BF747CQ40261576-1B177E2D-B122-4D41-B6F9-FDCBBD1A7313Q41029112-E6EDCB7C-11A7-47AA-8BCA-55B3971B2026Q41051646-4838CDE2-979B-4E3C-968C-062CC8EA2C44Q41465422-BE65B7DC-9C20-407F-9EE3-36B9EE0D9870Q41703176-4E890B0D-4584-4237-BB4E-8528620E8A81Q42522971-911066AB-B236-41CA-AE75-11416AE8C80F
P2860
HDAC6 as a target for neurodegenerative diseases: what makes it different from the other HDACs?
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@ast
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@en
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@nl
type
label
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@ast
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@en
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@nl
prefLabel
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@ast
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@en
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@nl
P2093
P2860
P3181
P356
P1476
HDAC6 as a target for neurodeg ...... ifferent from the other HDACs?
@en
P2093
Alessandra Nurisso
Esther Schenker
Muriel Cuendet
Vincent Zwick
P2860
P2888
P3181
P356
10.1186/1750-1326-8-7
P407
P5008
P577
2013-01-29T00:00:00Z
P5875
P6179
1007768963